10-Q: Oscar Health Reports Strong Q2 2024 Results Driven by Membership Growth and Improved Medical Cost Management

Oscar Health's Q2 2024 results show significant revenue growth and improved profitability, driven by a substantial increase in membership and better management of medical costs.

Summary

• Oscar Health reported a net income of $56.3 million for the second quarter of 2024, a significant improvement compared to a net loss of $15.4 million in the same period last year.
• Total revenue for the quarter reached $2.2 billion, up from $1.5 billion in Q2 2023, driven by a 47% increase in premium revenue.
• The company's membership grew to approximately 1.6 million as of June 30, 2024, a 63% increase year-over-year.
• The Medical Loss Ratio (MLR) improved to 79.0% in Q2 2024 from 79.9% in Q2 2023, indicating better management of medical expenses.
• The Selling, General, and Administrative (SG&A) Expense Ratio also improved to 19.6% from 22.2% year-over-year.
• Adjusted EBITDA for the quarter was $104.1 million, compared to $35.6 million in the same period last year.
• For the first six months of 2024, Oscar Health reported a net income of $233.8 million, compared to a net loss of $55.1 million in the first six months of 2023.
• The company's total revenue for the first six months of 2024 was $4.4 billion, up from $3.0 billion in the same period last year.
• The company has $2.3 billion in cash and cash equivalents as of June 30, 2024.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong financial results, significant membership growth, and improved cost management. The company's transition to profitability and positive trends in key metrics suggest a strong performance. However, the exit from the small group market and the non-renewal of the Cigna partnership are potential concerns.

Positives

• The company achieved a significant increase in net income, moving from a loss to a profit.
• There was substantial growth in membership, indicating strong market demand for Oscar's health plans.
• The improvement in the Medical Loss Ratio suggests effective cost management and pricing strategies.
• The reduction in the SG&A Expense Ratio demonstrates improved operational efficiency.
• The increase in investment income indicates effective management of the company's investment portfolio.
• The company has a strong cash position, providing financial flexibility.
• The company's total revenue for the first six months of 2024 was $4.4 billion, up from $3.0 billion in the same period last year.

Negatives

• The company is exiting the small group market and not renewing its partnership with Cigna after December 31, 2024.
• The company's risk adjustment transfers were higher as a percentage of premiums, which could impact future revenue.
• The company's medical expenses increased by 45% year-over-year, although this was offset by revenue growth and improved MLR.
• The company's selling, general and administrative expenses increased by 29% year-over-year.

Risks

• The company's risk adjustment transfer estimates are subject to a high degree of estimation and variability.
• The company is subject to ongoing reviews by various state insurance and healthcare regulatory authorities.
• The company is involved in legal proceedings, including a securities class action lawsuit.
• The company's business is affected by seasonal patterns of member enrollment and medical expenses.
• The company's reinsurance agreements do not relieve it of its primary medical claims incurred obligations.
• The company's investment portfolio is subject to interest rate risk.

Future Outlook

The company expects to continue to see consumers enrolling in ACA marketplace plans past July 2024 due to ongoing Medicaid redeterminations and an extended Special Enrollment Period. The company also expects to continue to manage medical costs and improve operational efficiency.

Management Comments

• Management believes that the company's operational and financial measures are useful in evaluating performance.
• Management believes that investors' understanding of the company's performance is enhanced by including the non-GAAP financial measure Adjusted EBITDA.
• Management believes that the company's reinsurance agreements help achieve important goals for the business, including risk management, capital efficiency, and greater predictability in earnings.

Industry Context

The results reflect a positive trend in the health insurance industry, with companies focusing on membership growth and cost management. The company's performance is also influenced by regulatory changes and market dynamics, such as Medicaid redeterminations and the Special Enrollment Period.

Comparison to Industry Standards

• The company's membership growth of 63% year-over-year is significantly higher than the industry average, indicating strong market penetration.
• The improvement in the Medical Loss Ratio (MLR) to 79.0% suggests that the company is managing medical costs more effectively than some of its peers.
• The company's Adjusted EBITDA of $104.1 million in Q2 2024 is a significant improvement compared to the same period last year, indicating a positive trend in profitability.
• The company's SG&A Expense Ratio of 19.6% is competitive with other health insurance companies, demonstrating efficient operational management.
• The company's investment income growth of 21% is also a positive sign, indicating effective management of its investment portfolio.

Management Changes

Legal Proceedings

• The company is currently involved in legal proceedings and other claims in the ordinary course of its business.
• A securities class action lawsuit against the company, certain of its directors and officers, and the underwriters that participated in the company's initial public offering was commenced on May 12, 2022.

Related Party Transactions

• In February 2022, the company issued the 2031 Notes to funds affiliated with or advised by Dragoneer Investment Group, LLC, Thrive Capital Management, LLC, LionTree Investment Management, LLC and Tenere Capital LLC.

Stakeholder Impact

• Shareholders will likely view the improved financial results and growth positively.
• Employees may benefit from the company's improved financial stability and growth prospects.
• Customers may experience better service and plan options due to the company's growth and investments.
• Suppliers and creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company will continue to offer Cigna+Oscar Small Group products through December 15, 2024.
• The company will provide transition and run-off services for the Cigna+Oscar Small Group plan through December 31, 2026.
• The company will continue to monitor regulatory developments and address bad actors in the market.
• The company will continue to manage medical costs and improve operational efficiency.

Key Dates

Keywords

health insurance, healthcare technology, membership growth, medical loss ratio, adjusted EBITDA, premium revenue, risk adjustment, financial results, quarterly report, OSCR